Mastalerz Lucyna, Celejewska-Wójcik Natalia, Ćmiel Adam, Wójcik Krzysztof, Szaleniec Joanna, Hydzik-Sobocińska Karolina, Tomik Jerzy, Sanak Marek
2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Department of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.
Clin Transl Allergy. 2023 Mar;13(3):e12235. doi: 10.1002/clt2.12235.
The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management.
Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients.
The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94.
Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD levels, asthma severity, and age of patients. The heterogeneity of non-eosinophilic N-ERD suggests a need for novel targeted interventions.
非甾体抗炎药加重的呼吸系统疾病(N-ERD)的细胞炎症模式具有异质性。然而,关于阿司匹林超敏反应的非嗜酸性粒细胞性哮喘(NEA)异质性的数据却很少。通过基于临床数据和类花生酸生物标志物对N-ERD患者进行检查,我们旨在识别可能指导临床管理的NEA内型。
从N-ERD患者中收集诱导痰。基于临床和实验室数据,将66例NEA患者(133例N-ERD患者中的49.6%)纳入层次聚类分析。使用具有不同指标的内部聚类验证评估聚类质量,并提出一个实用的决策树以简化患者分层。
最常见的NEA模式是少粒细胞性(PGA;75.8%),其余为中性粒细胞性哮喘(NA;24.2%)。识别出四个聚类。聚类#3包含最多的NEA患者(37.9%),具有严重哮喘和PGA模式(96.0%)。聚类#1(24.2%)仅包括严重哮喘患者,NA患病率较高(50%)。聚类#2(25.8%)包括控制良好的轻度或重度哮喘患者(PGA;76.5%)。聚类#4仅包含12.1%控制良好的中度哮喘患者(PGA;62.5%)。痰液前列腺素D水平将聚类#1与其余聚类区分开来,曲线下面积为0.94。
在识别出的四种NEA亚型中,聚类#3和#1代表患有严重哮喘但炎症特征不同的N-ERD患者。所有聚类可通过痰液PGD水平、哮喘严重程度和患者年龄进行区分。非嗜酸性粒细胞性N-ERD的异质性表明需要新的靶向干预措施。